Prof. Emirhan Nemutlu
'%3e%3cpath%20d='M22.1642%2019.0924C21.7317%2018.068%2021.1041%2017.1375%2020.3163%2016.3527C19.5309%2015.5656%2018.6006%2014.9381%2017.5766%2014.5048C17.5674%2014.5002%2017.5582%2014.4979%2017.5491%2014.4933C18.9774%2013.4616%2019.9059%2011.7811%2019.9059%209.88504C19.9059%206.74408%2017.3611%204.19922%2014.2201%204.19922C11.0792%204.19922%208.53429%206.74408%208.53429%209.88504C8.53429%2011.7811%209.46282%2013.4616%2010.8912%2014.4956C10.882%2014.5002%2010.8728%2014.5025%2010.8636%2014.5071C9.83652%2014.9404%208.91487%2015.5617%208.1239%2016.355C7.33685%2017.1404%206.70933%2018.0707%206.276%2019.0947C5.85031%2020.0972%205.62072%2021.172%205.59967%2022.2609C5.59905%2022.2853%205.60335%2022.3097%205.61229%2022.3325C5.62123%2022.3553%205.63465%2022.376%205.65174%2022.3935C5.66883%2022.4111%205.68926%2022.425%205.71182%2022.4345C5.73437%2022.444%205.7586%2022.4489%205.78308%2022.4489H7.15868C7.25956%2022.4489%207.3398%2022.3686%207.3421%2022.2701C7.38795%2020.5001%208.09868%2018.8425%209.35506%2017.5861C10.655%2016.2862%2012.3814%2015.5709%2014.2201%2015.5709C16.0588%2015.5709%2017.7852%2016.2862%2019.0852%2017.5861C20.3415%2018.8425%2021.0523%2020.5001%2021.0981%2022.2701C21.1004%2022.3709%2021.1807%2022.4489%2021.2815%2022.4489H22.6571C22.6816%2022.4489%2022.7058%2022.444%2022.7284%2022.4345C22.751%2022.425%2022.7714%2022.4111%2022.7885%2022.3935C22.8056%2022.376%2022.819%2022.3553%2022.8279%2022.3325C22.8369%2022.3097%2022.8412%2022.2853%2022.8406%2022.2609C22.8176%2021.165%2022.5907%2020.0989%2022.1642%2019.0924ZM14.2201%2013.8284C13.1678%2013.8284%2012.1773%2013.418%2011.4322%2012.6729C10.6871%2011.9278%2010.2767%2010.9374%2010.2767%209.88504C10.2767%208.83271%2010.6871%207.84227%2011.4322%207.09715C12.1773%206.35204%2013.1678%205.94165%2014.2201%205.94165C15.2724%205.94165%2016.2629%206.35204%2017.008%207.09715C17.7531%207.84227%2018.1635%208.83271%2018.1635%209.88504C18.1635%2010.9374%2017.7531%2011.9278%2017.008%2012.6729C16.2629%2013.418%2015.2724%2013.8284%2014.2201%2013.8284Z'%20fill='%238590A2'/%3e%3c/g%3e%3c/svg%3e)
Co-authors
Following
Followers
Research Focus & Metrics
Explore full metrics on Scilit
Academic Career Length
24Years (2003-Present)
(Calculated once Scilit publication data is synced: current year − year of first publication + 1)
Representative Publications
View All Publications1 October 2020 in Journal of Pharmaceutical and Biomedical Analysis
Journal Article
ÖZÖzge Cansın Zeki
Özge Cansın Zeki
CECemil Can Eylem
Cemil Can EylemTRTuba Reçber
Tuba Reçber
SKSedef Kır
Sedef Kır
Emirhan Nemutlu13 October 2022 in TrAC Trends in Analytical Chemistry
Journal Article
MWMuhammad Waris
Muhammad Waris
EKEngin Koçak
Engin Koçak
EGEkrem Murat Gonulalan
Ekrem Murat Gonulalan
LDL. Omur Demirezer
L. Omur Demirezer
SKSedef Kır
Sedef Kır
Emirhan Nemutlu15 November 2009 in Talanta
Journal Article
Emirhan NemutluSKSedef Kır
Sedef Kır
DKDoruk Katlan
Doruk Katlan
MBMehmet Sinan Beksac
Mehmet Sinan Beksac26 February 2022 in Journal of Pharmaceutical and Biomedical Analysis
Journal Article
TRTuba Reçber
Tuba Reçber
STSelin Seda Timur
Selin Seda Timur
SKSevilay Erdoğan Kablan
Sevilay Erdoğan Kablan
FYFatma Yalçın
Fatma Yalçın
TKTutku Ceren Karabulut
Tutku Ceren Karabulut
Emirhan Nemutlu +3
8 January 2021 in Communications Biology
Journal Article
ASAndrea Stojakovic
Andrea Stojakovic
STSergey Trushin
Sergey Trushin
ASAnthony Sheu
Anthony Sheu
LKLayla Khalili
Layla Khalili
SCSu-Youne Chang
Su-Youne Chang
ETEugenia Trushina
Eugenia Trushina +30
Alzheimer’s Disease (AD) is a devastating neurodegenerative disorder without a cure. Here we show that mitochondrial respiratory chain complex I is an important small molecule druggable target in AD. Partial inhibition of complex I triggers the AMP-activated protein kinase-dependent signaling network leading to neuroprotection in symptomatic APP/PS1 female mice, a translational model of AD. Treatment of symptomatic APP/PS1 mice with complex I inhibitor improved energy homeostasis, synaptic activity, long-term potentiation, dendritic spine maturation, cognitive function and proteostasis, and reduced oxidative stress and inflammation in brain and periphery, ultimately blocking the ongoing neurodegeneration. Therapeutic efficacy in vivo was monitored using translational biomarkers FDG-PET, 31P NMR, and metabolomics. Cross-validation of the mouse and the human transcriptomic data from the NIH Accelerating Medicines Partnership–AD database demonstrated that pathways improved by the treatment in APP/PS1 mice, including the immune system response and neurotransmission, represent mechanisms essential for therapeutic efficacy in AD patients.
1 January 2022 in TrAC Trends in Analytical Chemistry
Journal Article
GOGoksu Ozcelikay
Goksu OzcelikaySKS.I. Kaya
S.I. Kaya
EOE. Ozkan
E. Ozkan
Ahmet CETINKAYAEmirhan Nemutlu
Sibel Ozkan +1
About Me
Prof. Dr. Emirhan Nemutlu is a faculty member in the Department of Analytical Chemistry at Hacettepe University, Faculty of Pharmacy (Ankara, Türkiye). His research focuses on advanced analytical methodologies and multi-omics applications, including metabolomics, lipidomics, proteomics, and fluxomics, with particular emphasis on mass spectrometry–based platforms such as LC–MS/MS, GC–MS, and LC-HRMS technologies.
His work spans a wide range of applications, including cancer biomarker discovery, anti-doping analysis, natural product characterization, and precision medicine. He has extensive experience in both targeted and untargeted metabolomics, pathway-targeted analysis, and chemometric data integration, contributing to the identification of clinically relevant biomarkers and metabolic pathways.
Prof. Nemutlu has led and participated in numerous national and international research projects supported by TÜBİTAK and European collaborations. In addition to his research activities, he contributes to graduate education and curriculum development in analytical chemistry and bioanalysis. He has authored numerous peer-reviewed publications in high-impact journals. He currently serves as coordinator of the Bioanalytical and Omics Laboratory at Hacettepe University.